ANCN News and Press, Chemomab Therapeutics From 02/03/21

NEW YORK, NY / ACCESSWIRE / February 3, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in N...

Triterras (TRIT) -17%.SCYNEXIS (SCYX) -18% after initiates equity raise of $50M.ADDvantage Technologies Group (AEY) -13% on Q4 earnings release.Uxin (UXIN) -11% on FQ2 earnings release.Anchiano Therapeutics (ANCN) -11%.Sonnet BioTherapeutics Holdings (SONN)&...

Weissaw is investigating possible breaches of fiduciary duty and other violations of law by Anchiano Therapeutics ([[ANCN]] -16.0%) in connection with the proposed merger with Chemomab.Anchiano to combine with Chemomab via a reverse-merger to create a public company focused on advancing Chemo...

Concord Medical Services Holdings (CCM) -40%.vTv Therapeutics (VTVT) -33% after azeliragon flunks in mid-stage alzheimer’s and diabetes study.BioLineRx (BLRX) -27% despite promising motixafortide data in pancreatic cancer.NanoVibronix (NAOV) -17%.Galapagos (GLPG)&#x...

Gainers: Anchiano Therapeutics (ANCN) +142%.BioCardia (BCDA) +87%.Prevail Therapeutics (PRVL) +81%.Solid Biosciences (SLDB) +36%.OncoCyte (OCX) +24%.Bridgetown (BTWN) +23%.Contango Oil & Gas (MCF) +22%.Immutep (IMMP) +22%.MicroVision (MVIS) +20%.Sio Gene Therapies (SIOX) +1...

Anchiano Therapeutics (ANCN) and Chemomab, a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need entered into a definitive merger agreement, post which the shareholders of Chemomab would be...

Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing...

Assembly Biosciences (ASMB) -55% on Q3 earnings release.Global Blood Therapeutics (GBT) -32% on Q3 earnings release.Epizyme (EPZM) -23% on Q3 earnings release.Marin Software (MRIN) -14% on Q3 earnings release.Hall of Fame Resort & Entertainment (HOF...

Marin Software (MRIN) -24%.Aptinyx APTX -21% after prices equity offering.Weidai (WEI) -21%.InVivo Therapeutics (NVIV) -20%.Puhui Wealth Investment Management (PHCF) -18%.Insignia Systems (ISIG) -19%.Iterum Therapeutics (ITRM) -14%.Dragon Victory International (LYL) -12%.Tengasco (T...

Gainers: Marin Software (MRIN) +199%.Astrotech (ASTC) +108%.Creatd (CRTD) +42%.Snap (SNAP) +33%.Organovo (ONVO) +29%.VOC Energy Trust (VOC) +26%.9F (JFU) +23%.Calix (CALX) +21%.Marathon Patent (MARA) +21%.Establishment Labs (ESTA) +20%.Losers: Weidai (WEI) -54%.GSX Techedu (GSX...